Greenbrook is a leading provider of FDA-cleared, non-invasive mental health therapies positioned in the growing behavioral health market. The company has faced significant liquidity challenges and capital structure stress, recently transitioning to OTC trading after delisting from NASDAQ in 2023, though it now trades on OTC markets as GBNHF.
Cyborg Score Rationale
The company faces substantial operational and financial headwinds including liquidity constraints, multiple rounds of dilutive debt financing, and OTC market trading status. While the core TMS therapy business addresses a legitimate market need, execution challenges and capital availability have significantly impaired shareholder value.
Top Insights
Company delisted from NASDAQ and now trades OTC (GBNHF) with severely depressed stock price (~$0.01 as of late 2025)
Multiple rounds of debt financing from Madryn Asset Management and Greybrook Health indicate persistent liquidity pressures and reliance on specialized lenders
Neuronetics Inc. (STIM) agreed to acquire Greenbrook TMS in an all-stock transaction announced in August 2024, suggesting potential acquisition resolution
Operating network of FDA-cleared TMS and Spravato treatment centers provides differentiated therapeutic offerings in growing behavioral health sector despite financial distress
Named Competitors
Neurostar TMS System — Magnetic stimulation therapy for depression
Mental Health Services Network — Distributed outpatient psychiatric treatment
Telepsychiatry Platforms — Virtual mental health treatment delivery
Recent Developments
(Nov 2024) Q3 2024 operational and financial results announced
(Aug 2024) Neuronetics Inc. agreed to acquire Greenbrook TMS in all-stock transaction
(Oct 2024) Completed conversion of approximately US$10.5 million in convertible debt
Open the full interactive Greenbrook TMS Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.